The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Open accessAbstract
are discussed, as well as agents targeting these alterations. Current standards of treatment as well as promising future strategies are presented. Currently, more than fifteen targeted agents are food and Drug administration-approved for seven oncogenic drivers in non-small-cell lung cancer, highlighting the importance of actively searching for these mutations. Continuous and future efforts made in defining the biology of each of these alterations will help to elucidate their respective resistance mechanisms, and to define the best treatment strategy and therapeutic sequence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
The GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 700
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L., Satouchi, M., Chu, Q., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 645
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., Nagasubramanian, R., Davis, J. L., Rudzinski, E., Feraco, A. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30119-0 · Cited by 552
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 464
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Solomon, B. J., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Tang, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.4794 · Cited by 409
Lee, H.-H., Wang, Y.-N., Xia, W., Chen, C.-H., Rau, K.-M., Ye, L., Wei, Y., Chou, C.-K., Wang, S.-C., Yan, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.008 · Cited by 405
Who's still smoking? Disparities in adult cigarette smoking prevalence in the United States
Drope, J., Liber, A. C., Cahn, Z., Stoklosa, M., Kennedy, R., Douglas, C. E., Henson, R., & Drope, J. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21444 · Cited by 395
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 389
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz204 · Cited by 372
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Wu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Mazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., Peters, S., Dansin, E., Früh, M., Pless, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv573 · Cited by 325
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3701 · Cited by 301
CD74–NRG1 Fusions in Lung Adenocarcinoma
Fernandez-Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz-Cuaran, S., Peifer, M., Bos, M., Daßler, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0633 · Cited by 294
ROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A., Jenkins, C., Iyer, S., Schoenfeld, A., Keddy, C., & Davare, M. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 294
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
TRK inhibitors in TRK fusion-positive cancers
Drilon, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 291
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.006 · Cited by 289
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Camidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Lee, C. K., Davies, L., Wu, Y.-L., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw279 · Cited by 252
The epidermal growth factor receptor family
Bazley, L. A., & Gullick, W. J. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01032 · Cited by 250
Detection of NRG1 Gene Fusions in Solid Tumors
Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., Ma, P. C., Nieva, J. J., Spira, A. I., Vanderwalde, A. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0160 · Cited by 227
Lin, J. J., Liu, S. V., McCoach, C. E., Zhu, V. W., Tan, A. C., Yoda, S., Peterson, J., Do, A., Prutisto-Chang, K., Dagogo-Jack, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.015 · Cited by 227
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
Ferrara, R., Auger, N., Auclin, E., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.021 · Cited by 218
Patil, T., Smith, D. E., Bunn, P. A., Aisner, D. L., Le, A. T., Hancock, M., Purcell, W. T., Bowles, D. W., Camidge, D. R., & Doebele, R. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.001 · Cited by 205
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P. J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz407 · Cited by 197
Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., Price, L. S. L., Zirkelbach, J. F., Li, Y., Liu, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3558 · Cited by 171
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
Tognon, C. E., Garnett, M. J., Kenward, E., Kay, R., Morrison, K. B., & Sorensen, P. H. B. (2001) · PubMed · Cited by 154
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Guan, J., Umapathy, G., Yamazaki, Y., Wolfstetter, G., Mendoza-García, P., Pfeifer, K., Mohammed, A., Hugosson, F., Zhang, H., Hsu, A. W., et al. (2015) · eLife · doi:10.7554/elife.09811 · Cited by 150
Symptoms and the early diagnosis of lung cancer
Birring, S., & Peake, M. D. (2005) · Thorax · doi:10.1136/thx.2004.032698 · Cited by 142
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31076-5 · Cited by 140
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
Lin, J. J., Ritterhouse, L. L., Ali, S. M., Bailey, M., Schrock, A. B., Gainor, J. F., Ferris, L. A., Mino-Kenudson, M. A., Miller, V. A., Iafrate, A. J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.004 · Cited by 133
The HER receptor family: a rich target for therapeutic development
MASS, R. D. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.093 · Cited by 127
Yun, M. R., Kim, D. H., Kim, S., Joo, H.-S., Lee, Y. W., Choi, H. M., Park, C. W., Heo, S. G., Kang, H. N., Lee, S. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2777 · Cited by 125
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
Self-citationSmit, E. F., Nakagawa, K., Nagasaka, M., Felip, E., Goto, Y., Li, B. T., Pacheco, J. M., Murakami, H., Barlési, F., Saltos, A. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9504 · Cited by 117
Friedlaender, A., Banna, G. L., Malapelle, U., Pisapia, P., & Addeo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00166 · Cited by 106
Self-citationKras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
Lin, J. J., Schoenfeld, A. J., Zhu, V. W., Yeap, B. Y., Chin, E. N., Rooney, M. M., Plodkowski, A. J., Digumarthy, S. R., Dagogo‐Jack, I., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.014 · Cited by 85
Shin, D. H., Lee, D., Hong, D. W., Hong, S. H., Hwang, J.-A., Lee, B. I., You, H. J., Lee, G. K., Kim, I.-H., Lee, Y.-S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11913 · Cited by 81
Gainor, J. F., Curigliano, G., Kim, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9515 · Cited by 74
Cho, B. C., Drilon, A. E. D. C., Doebele, R. C., Kim, D., Lin, J. J., Lee, J., Ahn, M., Zhu, V. W., Ejadi, S., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9011 · Cited by 70
Frisone, D., Friedlaender, A., Malapelle, U., Banna, G. L., & Addeo, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103008 · Cited by 68
Self-citationNTRK Fusion-positive Non–small-cell Lung Cancer: The Diagnosis and Targeted Therapy
Haratake, N., & Seto, T. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.013 · Cited by 67
International Association for the Study of Lung Cancer
Colditz, G. A. (2007) · Sage eBooks · doi:10.4135/9781412953979.n308 · Cited by 66
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Friedlaender, A., Banna, G. L., Buffoni, L., & Addeo, A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0852-9 · Cited by 55
Self-citationRecent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
Guo, Y., Cao, R., Zhang, X., Huang, L., Sun, L., Zhao, J., Ma, J., & Han, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s230309 · Cited by 55
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
Addeo, A., Tabbò, F., Robinson, T., Buffoni, L., & Novello, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.015 · Cited by 53
Self-citationChen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., Qian, L., Chen, G., Zhou, E., Guo, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00811 · Cited by 52
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
Ou, S. I., & Zhu, V. W. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100037 · Cited by 51
Moro‐Sibilot, D., Faivre, L., Zalcman, G., Pérol, M., Barlési, F., Otto, J., Monnet, I., Cortot, A. B., Wislez, M., Léna, H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8065 · Cited by 48
Gardini, A. C., Chiadini, E., Faloppi, L., Marisi, G., Delmonte, A., Scartozzi, M., Loretelli, C., Lucchesi, A., Oboldi, D., Dubini, A., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2463-2 · Cited by 43
Solomon, B., Zhou, C. C., Drilon, A. E. D. C., Park, K., Wolf, J., Elamin, Y. Y., Davis, H. M., Soldatenkova, V., Sashegyi, A. I., Bence, A. K., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0935 · Cited by 43
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Shin, D. H., Jo, J. Y., & Han, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1178 · Cited by 42
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
Friedlaender, A., Banna, G. L., Patel, S. H., & Addeo, A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0675-9 · Cited by 41
Self-citationKordiak, J., Szemraj, J., Grabska-Kobylecka, I., Bialasiewicz, P., Braun, M., Kordek, R., & Nowak, D. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2779-1 · Cited by 38
Sereno, M., Moreno, V., Moreno‐Rubio, J., Gómez-Raposo, C., Sánchez, S. G., Jusdado, R. H., Falagán, S., Tévar, F. Z., & Sáenz, E. C. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000277 · Cited by 37
Cheema, P. K., Doherty, M. K., & Tsao, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.033 · Cited by 36
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
Shitara, K., Yamazaki, K., Tsushima, T., Naito, T., Matsubara, N., Watanabe, M., Sarholz, B., Johne, A., & Doi, T. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa042 · Cited by 35
Kim, D., Lee, K. H., Han, J., Lee, J.-S., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J.-S., Min, Y. J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.007 · Cited by 34
Chen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., Qian, L., Chen, G., Zhou, E., Guo, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.661128 · Cited by 34
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
Lin, J. J., Johnson, T. W., Lennerz, J. K., Lee, C., Hubbeling, H., Yeap, B. Y., Dagogo‐Jack, I., Gainor, J. F., & Shaw, A. T. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9611 · Cited by 22
Lang, D., Huemer, F., Rinnerthaler, G., Horner, A., Wass, R. E., Brehm, E., Akbari, K., Granitz, M., Hutarew, G., Kaiser, B., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00679-9 · Cited by 21
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang, S., Yang, Z., & Wang, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.4524 · Cited by 10
Skrzypski, M. T., Szymanowska-Narloch, A., & Dziadziuszko, R. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.70116 · Cited by 10
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
Addeo, A., & Metro, G. (2018) · Drugs in Context · doi:10.7573/dic.212537 · Cited by 3
Self-citation
Cited by
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Wu, Y.-L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J.-S., Zhong, W., Horinouchi, H., Mao, W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310532 · Cited by 431
Bench-to-bedside imaging in brain metastases: a road to precision oncology
Shukla, S., Karbhari, A., Rastogi, S., Agarwal, U., Rai, P., & Mahajan, A. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.02.015 · Cited by 12
Metadata
- Authors
- Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A.
- Venue
- World Journal of Clinical Oncology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2021-04-24
- Volume
- 12
- Issue
- 4
- Pages
- 217-237
- ISSN
- 2218-4333 (ISSN-L)
- OpenAlex
- W3155376330
- Cited by
- 316
- References
- 120
- FWCI
- 24.54
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.